211 related articles for article (PubMed ID: 17595892)
1. Suppression of gastric acid with intravenous esomeprazole and omeprazole: results of 3 studies in healthy subjects.
Röhss K; Wilder-Smith C; Kilhamn J; Fjellman M; Lind T
Int J Clin Pharmacol Ther; 2007 Jun; 45(6):345-54. PubMed ID: 17595892
[TBL] [Abstract][Full Text] [Related]
2. Review article: pharmacology of esomeprazole and comparisons with omeprazole.
Dent J
Aliment Pharmacol Ther; 2003 Feb; 17 Suppl 1():5-9. PubMed ID: 12614299
[TBL] [Abstract][Full Text] [Related]
3. Acid-inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori-negative healthy subjects.
Geus WP; Mulder PG; Nicolai JJ; Van den Boomgaard DM; Lamers CB
Aliment Pharmacol Ther; 1998 Apr; 12(4):329-35. PubMed ID: 9690721
[TBL] [Abstract][Full Text] [Related]
4. Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized clinical studies.
Wilder-Smith CH; Bondarov P; Lundgren M; Niazi M; Röhss K; Ahlbom H; Nyman L
Eur J Gastroenterol Hepatol; 2005 Feb; 17(2):191-7. PubMed ID: 15674097
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole.
Andersson T; Röhss K; Bredberg E; Hassan-Alin M
Aliment Pharmacol Ther; 2001 Oct; 15(10):1563-9. PubMed ID: 11563995
[TBL] [Abstract][Full Text] [Related]
6. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Miner P; Katz PO; Chen Y; Sostek M
Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
[TBL] [Abstract][Full Text] [Related]
7. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.
Timmer W; Ripke H; Kleist P; Ehrlich A; Wieckhorst G; Lücker PW; Fuder H
Methods Find Exp Clin Pharmacol; 1995 Sep; 17(7):489-95. PubMed ID: 8577212
[TBL] [Abstract][Full Text] [Related]
8. The comparative effects of single intravenous doses of omeprazole and famotidine on intragastric pH.
Abe Y; Inamori M; Togawa J; Kikuchi T; Muramatsu K; Chiguchi G; Kawamura H; Kobayashi N; Kirikoshi H; Sakaguchi T; Takamura T; Nakajima A; Ueno N; Sekihara H
J Gastroenterol; 2004 Jan; 39(1):21-5. PubMed ID: 14767730
[TBL] [Abstract][Full Text] [Related]
9. A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease.
Periclou AP; Goldwater R; Lee SM; Park DW; Kim DY; Cho KD; Boileau F; Jung WT
Clin Pharmacol Ther; 2000 Sep; 68(3):304-11. PubMed ID: 11014412
[TBL] [Abstract][Full Text] [Related]
10. A single dose of intravenous esomeprazole decreases gastric secretion in healthy volunteers.
Nichita C; Abdou AE; Maerten P; Herranz M; Mouret N; Thalmann C; Michetti PF; Dorta G
Aliment Pharmacol Ther; 2009 Nov; 30(10):1022-9. PubMed ID: 19702644
[TBL] [Abstract][Full Text] [Related]
11. Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study.
Wilder-Smith CH; Röhss K; Bondarov P; Hallerbäck B; Svedberg LE; Ahlbom H
Aliment Pharmacol Ther; 2004 Nov; 20(10):1099-104. PubMed ID: 15569112
[TBL] [Abstract][Full Text] [Related]
12. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Röhss K; Lind T; Wilder-Smith C
Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, pharmacodynamics, and safety of esomeprazole injection/infusion in healthy Chinese volunteers: a five-way crossover study.
Yang H; Li J; Zhao Q; Li J; Shen K; Yang X; Jiang J; Hu P; Qian J
J Gastroenterol Hepatol; 2013 Dec; 28(12):1823-8. PubMed ID: 23800161
[TBL] [Abstract][Full Text] [Related]
14. Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects.
Bruley des Varannes S; Gharib H; Bicheler V; Bost R; Bonaz B; Stanescu L; Delchier JC; Bonnot-Marlier S
Aliment Pharmacol Ther; 2004 Oct; 20(8):899-907. PubMed ID: 15479362
[TBL] [Abstract][Full Text] [Related]
15. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z.
Hunt RH; Armstrong D; Yaghoobi M; James C; Chen Y; Leonard J; Shin JM; Lee E; Tang-Liu D; Sachs G
Aliment Pharmacol Ther; 2008 Jul; 28(2):187-99. PubMed ID: 18445141
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics during treatment with the omeprazole 20 mg enteric-coated tablet and 20 mg capsule in asymptomatic duodenal ulcer patients.
Thomson AB; Kirdeikis P; Lastiwka R; Röhss K; Sinclair P; Olofsson B
Can J Gastroenterol; 1997; 11(8):657-60. PubMed ID: 9459044
[TBL] [Abstract][Full Text] [Related]
17. The effects of oral doses of lansoprazole and omeprazole on gastric pH.
Tolman KG; Sanders SW; Buchi KN; Karol MD; Jennings DE; Ringham GL
J Clin Gastroenterol; 1997 Mar; 24(2):65-70. PubMed ID: 9077718
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of intravenous esomeprazole at 2 different dosages in dogs.
Seo DH; Lee JB; Hwang JH; Jeong JW; Song GH; Koo TS; Seo KW
J Vet Intern Med; 2019 Mar; 33(2):531-535. PubMed ID: 30548689
[TBL] [Abstract][Full Text] [Related]
19. Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects.
Armstrong D; Bair D; James C; Tanser L; Escobedo S; Nevin K
Aliment Pharmacol Ther; 2003 Oct; 18(7):705-11. PubMed ID: 14510744
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs.
Hwang JH; Jeong JW; Song GH; Koo TS; Seo KW
J Vet Intern Med; 2017 May; 31(3):743-750. PubMed ID: 28407418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
